Drugs / HL2351
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02175056 | May 2014 → Jan 2015 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02853084 | Oct 2015 → May 2017 | cryopyrin-associated periodic syndrome | Handok Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HL2351 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02175056 ↗ |
| Route | Subcutaneous | “the study drug or placebo is subcutaneously administered for the relevant dose group.” NCT02175056 ↗ |